Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same author

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Proinflammatory Epstein-Barr Virus Antibody Functions Track with Disease Activity in Multiple Sclerosis.

Annals of neurology·2026
Same author

Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.

Brain : a journal of neurology·2026
Same author

Live Attenuated Measles-Mumps-Rubella and Varicella Vaccinations and Multiple Sclerosis Activity.

JAMA network open·2026
Same author

A glial oxidative signature predicts disability in primary progressive multiple sclerosis and is associated with long-term cognitive decline.

Frontiers in immunology·2026

Related Experiment Video

Updated: May 4, 2026

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
08:23

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

11.0K

Body fluid biomarkers in multiple sclerosis.

Manuel Comabella1, Xavier Montalban1

  • 1Department of Neurology and Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya, Cemcat, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

The Lancet. Neurology
|December 17, 2013
PubMed
Summary

Biomarkers are crucial for understanding multiple sclerosis (MS) heterogeneity, aiding diagnosis, and predicting treatment response. However, a significant gap exists between proposed and clinically applied MS biomarkers.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

3.8K

Related Experiment Videos

Last Updated: May 4, 2026

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
08:23

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

11.0K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

3.8K

Area of Science:

  • Neurology
  • Biomarker Discovery
  • Clinical Research

Background:

  • Multiple sclerosis (MS) is a heterogeneous neurological disease.
  • Biomarkers offer potential for MS diagnosis, prognosis, and treatment monitoring.
  • The heterogeneity of MS necessitates robust biomarker strategies.

Purpose of the Study:

  • To highlight the critical role of biomarkers in multiple sclerosis research.
  • To underscore the unmet need for validated and clinically applicable biomarkers in MS.
  • To identify the gaps in the translation of exploratory biomarkers to routine practice.

Main Methods:

  • Review of current literature on MS biomarkers.
  • Analysis of the challenges in biomarker validation and clinical integration.
  • Discussion of the spectrum from exploratory to validated biomarkers.

Main Results:

  • Biomarkers are essential for managing MS complexity.
  • Significant research efforts have identified numerous exploratory biomarkers.
  • A substantial gap persists between research findings and clinical utility.

Conclusions:

  • Validated biomarkers are crucial for advancing multiple sclerosis care.
  • Bridging the gap between exploratory and clinical biomarkers remains a key challenge.
  • Further efforts are needed to integrate reliable biomarkers into routine MS management.